These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 17577204)
1. Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells. Allegra A; Oteri G; Nastro E; Alonci A; Bellomo G; Del Fabro V; Quartarone E; Alati C; De Ponte FS; Cicciù D; Musolino C Hematol Oncol; 2007 Dec; 25(4):164-9. PubMed ID: 17577204 [TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws. Allegra A; Alonci A; Penna G; Granata A; Nastro Siniscalchi E; Oteri G; Loddo S; Teti D; Cicciù D; De Ponte FS; Musolino C Acta Haematol; 2010; 124(2):79-85. PubMed ID: 20639624 [TBL] [Abstract][Full Text] [Related]
3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538 [TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414 [TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405 [TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. King AE; Umland EM Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663 [TBL] [Abstract][Full Text] [Related]
7. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review]. Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077 [TBL] [Abstract][Full Text] [Related]
8. Dental and periodontal history of oncologic patients on parenteral bisphosphonates with or without osteonecrosis of the jaws: a pilot study. Carmagnola D; Celestino S; Abati S Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Dec; 106(6):e10-5. PubMed ID: 18801674 [TBL] [Abstract][Full Text] [Related]
9. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. Bagan JV; Murillo J; Jimenez Y; Poveda R; Milian MA; Sanchis JM; Silvestre FJ; Scully C J Oral Pathol Med; 2005 Feb; 34(2):120-3. PubMed ID: 15641993 [TBL] [Abstract][Full Text] [Related]
10. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. Badros A; Terpos E; Katodritou E; Goloubeva O; Kastritis E; Verrou E; Zervas K; Baer MR; Meiller T; Dimopoulos MA J Clin Oncol; 2008 Dec; 26(36):5904-9. PubMed ID: 19018084 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and jaw osteonecrosis: the UAMS experience. Clarke BM; Boyette J; Vural E; Suen JY; Anaissie EJ; Stack BC Otolaryngol Head Neck Surg; 2007 Mar; 136(3):396-400. PubMed ID: 17321866 [TBL] [Abstract][Full Text] [Related]
12. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738 [TBL] [Abstract][Full Text] [Related]
13. Clinical guidelines for prevention of osteonecrosis of the jaws in patients in treatment with bisphosphonates: literature review and report of three cases. Sarzi Amadè D; Tallarico M; Loreti MC; Montecchi PP; Niccoli A Minerva Stomatol; 2008 Sep; 57(9):429-46. PubMed ID: 18923378 [TBL] [Abstract][Full Text] [Related]
14. [A case of osteonecrosis of the lower jaw due to bisphosphonates in a breast cancer patient with bone metastasis]. Kubo N; Katayama K; Ishizaki A; Morinaga N; Negishi T; Kuwano H Gan To Kagaku Ryoho; 2008 Nov; 35(11):1973-5. PubMed ID: 19011355 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. Kyrgidis A; Vahtsevanos K; Koloutsos G; Andreadis C; Boukovinas I; Teleioudis Z; Patrikidou A; Triaridis S J Clin Oncol; 2008 Oct; 26(28):4634-8. PubMed ID: 18574158 [TBL] [Abstract][Full Text] [Related]
16. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Walter C; Al-Nawas B; du Bois A; Buch L; Harter P; Grötz KA Cancer; 2009 Apr; 115(8):1631-7. PubMed ID: 19156913 [TBL] [Abstract][Full Text] [Related]
17. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw. Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504 [TBL] [Abstract][Full Text] [Related]
18. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Christodoulou C; Pervena A; Klouvas G; Galani E; Falagas ME; Tsakalos G; Visvikis A; Nikolakopoulou A; Acholos V; Karapanagiotidis G; Batziou E; Skarlos DV Oncology; 2009; 76(3):209-11. PubMed ID: 19212145 [TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. Lazarovici TS; Yahalom R; Taicher S; Elad S; Hardan I; Yarom N J Oral Maxillofac Surg; 2009 Apr; 67(4):850-5. PubMed ID: 19304045 [TBL] [Abstract][Full Text] [Related]
20. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]